来自意大利指南的药物经济分析,用于治疗前乳腺瘤
Michele Basile1, Ilaria Valentini1, Roberto Attanasio2
1High School of Economy and Management of Health Systems, Catholic University of Sacred Heart, Rome.
Global & regional health technology assessment
|January 17, 2024
概括
卡伯戈林在治疗前乳腺瘤方面具有很好的价值,但内镜手术显示出更高的成本效益. 考虑手术作为最初的方法可能会改善患者的治疗结果和资源配置.
科学领域:
- 内分泌学 在内分泌学.
- 卫生经济学 卫生经济学
- 在瘤学瘤学.
背景情况:
- 甲状腺瘤是最常见的垂体腺瘤,通常使用多巴胺激动剂 (DA) 进行治疗,如卡伯戈林.
- 手术是二线选择,放射治疗只适用于治疗失败或复发的巨细胞瘤.
研究的目的:
- 评估意大利对益生菌瘤管理的经济证据.
- 对各种治疗方案进行疾病成本和成本效益分析.
主要方法:
- 对研究问题进行系统的文献审查.
- 专家小组调查,以确定每个治疗程序的成本驱动因素.
主要成果:
- 一年治疗费用:2,558.91欧元 (微型乳腺瘤) 和3,287.40欧元 (宏型乳腺瘤).
- 后续费用:从第二到第五年每年798.13欧元至1,084.59欧元.
- 卡伯戈林表现出良好的成本效益 (ICER 3,201.15欧元与烯胺相比).
- 内镜手术比卡伯戈林更具成本效益 (ICER €44,846.64).
结论:
- 下垂体手术具有有利的成本效益概况和安全性,值得考虑作为初始治疗.
- 采用手术作为主要治疗方法可能会改善患者的治疗结果,并优化医疗保健资源分配.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
148
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
148
Analysis of Population Pharmacokinetic Data
263
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
263
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
129
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
129
Psychosis: Goals of Pharmacotherapy
133
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
133
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K


